BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 9732389)

  • 1. Antiplatelet efficacy of XV459, a novel nonpeptide platelet GPIIb/IIIa antagonist: comparative platelet binding profiles with c7E3.
    Mousa SA; Bozarth JM; Lorelli W; Forsythe MS; Thoolen MJ; Slee AM; Reilly TM; Friedman PA
    J Pharmacol Exp Ther; 1998 Sep; 286(3):1277-84. PubMed ID: 9732389
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel nonpeptide antiplatelet glycoprotein IIb/IIIa receptor antagonist, DMP754: receptor binding affinity and specificity.
    Mousa SA; Forsythe M; Lorelli W; Bozarth J; Xue CB; Wityak J; Sielecki TM; Olson RE; DeGrado W; Kapil R; Hussain M; Wexler R; Thoolen MJ; Reilly TM
    Coron Artery Dis; 1996 Oct; 7(10):767-74. PubMed ID: 8970768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. XV454, a novel nonpeptide small-molecule platelet GIIb/IIIa antagonist with comparable platelet alpha(IIb)beta3-binding kinetics to c7E3.
    Mousa SA; Forsythe M; Bozarth J; Youssef A; Wityak J; Olson R; Sielecki T
    J Cardiovasc Pharmacol; 1998 Nov; 32(5):736-44. PubMed ID: 9821847
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Platelet GPIIb/IIIa antagonist, XV459, in heparin-induced thrombocytopenia.
    Mousa SA; Ahmad S
    Am J Hematol; 2007 Apr; 82(4):276-82. PubMed ID: 17039513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral antiplatelet efficacy and specificity of a novel nonpeptide platelet GPIIb/IIIa receptor antagonist, DMP 802.
    Mousa SA; Olson RE; Bozarth JM; Lorelli W; Forsythe MS; Racanelli A; Gibbs S; Schlingman K; Bozarth T; Kapil R; Wityak J; Sielecki TM; Wexler RR; Thoolen MJ; Slee A; Reilly TM; Anderson PS; Friedman PA
    J Cardiovasc Pharmacol; 1998 Aug; 32(2):169-76. PubMed ID: 9700976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral antiplatelet efficacy of the platelet GPIIb/IIIa antagonist, DMP754 in non-human primates.
    Mousa SA; Bozarth J; Youssef A; Levine B
    Thromb Res; 1998 Mar; 89(5):217-25. PubMed ID: 9645915
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of platelet-mediated clot retraction by integrin antagonists.
    Hantgan RR; Mousa SA
    Thromb Res; 1998 Mar; 89(6):271-9. PubMed ID: 9669749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous and oral antithrombotic efficacy of the novel platelet GPIIb/IIIa antagonist roxifiban (DMP754) and its free acid form, XV459.
    Mousa SA; Kapil R; Mu DX
    Arterioscler Thromb Vasc Biol; 1999 Oct; 19(10):2535-41. PubMed ID: 10521384
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Platelet GPIIb/IIIa binding characteristics of small molecule RGD mimetic: distinct binding profile for Roxifiban.
    Mousa SA; Bozarth JM; Naik UP; Slee A
    Br J Pharmacol; 2001 Jun; 133(3):331-6. PubMed ID: 11375248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative in vitro efficacy of different platelet glycoprotein IIb/IIIa antagonists on platelet-mediated clot strength induced by tissue factor with use of thromboelastography: differentiation among glycoprotein IIb/IIIa antagonists.
    Mousa SA; Khurana S; Forsythe MS
    Arterioscler Thromb Vasc Biol; 2000 Apr; 20(4):1162-7. PubMed ID: 10764688
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human platelet alphaIIbeta3 integrin binding affinity and specificity of SJ874: antiplatelet efficacy versus aspirin.
    Mousa SA; Forsythe M; Bozarth J; Jin F; Confalone PN
    Coron Artery Dis; 2000 Oct; 11(7):563-70. PubMed ID: 11023245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Orally active isoxazoline glycoprotein IIb/IIIa antagonists with extended duration of action.
    Olson RE; Sielecki TM; Wityak J; Pinto DJ; Batt DG; Frietze WE; Liu J; Tobin AE; Orwat MJ; Di Meo SV; Houghton GC; Lalka GK; Mousa SA; Racanelli AL; Hausner EA; Kapil RP; Rabel SR; Thoolen MJ; Reilly TM; Anderson PS; Wexler RR
    J Med Chem; 1999 Apr; 42(7):1178-92. PubMed ID: 10197962
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of low molecular weight GP IIb/IIIa antagonists that bind preferentially to activated platelets.
    Bednar RA; Gaul SL; Hamill TG; Egbertson MS; Shafer JA; Hartman GD; Gould RJ; Bednar B
    J Pharmacol Exp Ther; 1998 Jun; 285(3):1317-26. PubMed ID: 9618439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New orally active non-peptide fibrinogen receptor (GpIIb-IIIa) antagonists: identification of ethyl 3-[N-[4-[4-[amino[(ethoxycarbonyl) imino]methyl]phenyl]-1,3-thiazol-2-yl]-N-[1-[(ethoxycarbonyl)methyl]pip erid -4-yl]amino]propionate (SR 121787) as a potent and long-acting antithrombotic agent.
    Badorc A; Bordes MF; de Cointet P; Savi P; Bernat A; Lalé A; Petitou M; Maffrand JP; Herbert JM
    J Med Chem; 1997 Oct; 40(21):3393-401. PubMed ID: 9341914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The fibrinogen gamma chain dodecapeptide inhibits agonist-induced aggregation of rabbit platelets and fibrinogen binding to rabbit glycoprotein IIb-IIIa.
    Rand ML; Packham MA; Taylor DM; Yeo EL; Gemmell CH; Patil S; Lam SC
    Thromb Haemost; 1999 Dec; 82(6):1680-6. PubMed ID: 10613655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous and oral antiplatelet/antithrombotic efficacy and specificity of XR300, a novel nonpeptide platelet GPIIb/IIIa antagonist.
    Mousa SA; Forsythe M; Wityak J; Bozarth J; Mu DX
    J Cardiovasc Pharmacol; 1998 Mar; 31(3):441-8. PubMed ID: 9514190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of platelet glycoprotein IIb/IIIa activation by 3,4-methylenedioxy-beta-nitrostyrene, a novel tyrosine kinase inhibitor.
    Wang WY; Wu YC; Wu CC
    Mol Pharmacol; 2006 Oct; 70(4):1380-9. PubMed ID: 16837624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of glycoprotein IIb/IIIa inhibitors on CD62p expression, platelet aggregates, and microparticles in vitro.
    Matzdorff AC; Kühnel G; Kemkes-Matthes B; Pralle H; Voss R; Fareed J
    J Lab Clin Med; 2000 Mar; 135(3):247-55. PubMed ID: 10711863
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In-vitro efficacy of different platelet glycoprotein IIb/IIIa antagonists and thrombolytics on platelet/fibrin-mediated clot dynamics in human whole blood using thrombelastography.
    Mousa SA
    Blood Coagul Fibrinolysis; 2007 Jan; 18(1):55-60. PubMed ID: 17179828
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential antiplatelet efficacy for various GPIIb/IIIa antagonists: role of plasma calcium levels.
    Mousa SA; Bozarth JM; Forsythe MS; Slee A
    Cardiovasc Res; 2000 Sep; 47(4):819-26. PubMed ID: 10974231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.